HomeCompareOCEL vs EPRT

OCEL vs EPRT: Dividend Comparison 2026

OCEL yields 72.93% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCEL wins by $1.14M in total portfolio value
10 years
OCEL
OCEL
● Live price
72.93%
Share price
$2.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.20M
Annual income
$325,655.22
Full OCEL calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — OCEL vs EPRT

📍 OCEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCELEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCEL + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCEL pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCEL
Annual income on $10K today (after 15% tax)
$6,198.72/yr
After 10yr DRIP, annual income (after tax)
$276,806.94/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, OCEL beats the other by $265,892.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCEL + EPRT for your $10,000?

OCEL: 50%EPRT: 50%
100% EPRT50/50100% OCEL
Portfolio after 10yr
$633.7K
Annual income
$169,247.97/yr
Blended yield
26.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

OCEL
No analyst data
Altman Z
-38.0
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCEL buys
0
EPRT buys
0
No recent congressional trades found for OCEL or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCELEPRT
Forward yield72.93%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$1.20M$63.4K
Annual income after 10y$325,655.22$12,840.73
Total dividends collected$1.03M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: OCEL vs EPRT ($10,000, DRIP)

YearOCEL PortfolioOCEL Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$17,993$7,292.62$11,205$505.18+$6.8KOCEL
2$31,515$12,262.92$12,672$682.46+$18.8KOCEL
3$53,795$20,073.98$14,490$930.48+$39.3KOCEL
4$89,585$32,023.91$16,786$1,282.69+$72.8KOCEL
5$145,696$49,840.41$19,753$1,791.56+$125.9KOCEL
6$231,650$75,755.11$23,677$2,541.64+$208.0KOCEL
7$360,433$112,567.38$29,008$3,672.99+$331.4KOCEL
8$549,352$163,689.57$36,463$5,425.08+$512.9KOCEL
9$820,973$233,165.47$47,238$8,221.57+$773.7KOCEL
10$1,204,096$325,655.22$63,385$12,840.73+$1.14MOCEL

OCEL vs EPRT: Complete Analysis 2026

OCELStock

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.

Full OCEL Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this OCEL vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCEL vs SCHDOCEL vs JEPIOCEL vs OOCEL vs KOOCEL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.